Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.

Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A. +12 more·2019·Endocrine Practice
DOI 10.4158/cs-2018-0535

Cited by (296)

Items 101–200 of 296

  1. A comparison of clinical pharmacist management of type 2 diabetes versus usual care in a federally qualified health center
    Rhianna M Fink, Emanuela V. Mooney, Joseph J. Saseen, Sarah J. Billups · 2019 · Pharmacy Practice
  2. Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications
    Elizabeth M. Vaughan, Jaime J. Rueda, Susan Leanne Samson, David J. Hyman · 2020 · Current Diabetes Reviews
  3. Effectiveness of V-Go(®) for patients with type 2 diabetes in a real-world setting: A prospective observational study
    Grunberger, George, Rosenfeld, Cheryl R., Bode, Bruce W., Abbott, Scott D., Nikkel, Carla, Shi, Leon, Strange, Poul · 2020 · Drugs - Real World Outcomes
  4. When does diabetes start? Early detection and intervention in type 2 diabetes mellitus
    Fernando Gómez Peralta, Cristina Abreu, Xavier Cos, Ricardo Gómez‐Huelgas · 2020 · Revista Clínica Española (English Edition)
  5. Knowledge, Attitude, and Practice Regarding Diabetes Mellitus Among Type 2 Diabetic Patients Attending Primary Health Care Centers in the Jazan Region of Saudi Arabia
    Mohammad Mahzari, Omar Oraibi, Ayman Shami, Mohammed O. Shami, Tayeb Y Thobab, Abdulaziz Awlaqi, Roaa A Abu Allah, Fahad Azyabi, Faisal A Otaif, Khalid Majrashi et al. · 2022 · Cureus
  6. Holistic and Personalized Strategies for Managing in Elderly Type 2 Diabetes Patients
    Jae‐Seung Yun, Kyuho Kim, Yu‐Bae Ahn, Kyungdo Han, Seung‐Hyun Ko · 2024 · Diabetes & Metabolism Journal
  7. Poor glycemic control in workers with diabetes mellitus in relation to long working hours: a cross-sectional study
    Jongin Lee, Hyoung‐Ryoul Kim, Tae Won Jang, Dong‐Wook Lee, Chaiho Jeong, Mo‐Yeol Kang · 2020 · Industrial Health
  8. System Dynamic Model Simulates the Growth Trend of Diabetes Mellitus in Chinese Population: Implications for Future Urban Public Health Governance
    Hao Li, Guo-Ying Chang, Yihong Jiang, Li Xu, Long Shen, Zhi‐Chun Gu, Hou‐Wen Lin, Fang‐Hong Shi · 2022 · International Journal of Public Health
  9. Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis
    Adili Tuersun, Guanxin Hou, Gang Cheng · 2024 · The American Journal of the Medical Sciences
  10. Evaluating glucose‐lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial
    Alan J. Sinclair, Simon R. Heller, Richard E. Pratley, Ran Duan, Robert J. Heine, Andreas Festa, Jacek I. Kiljanski · 2020 · Diabetes Obesity and Metabolism
  11. Incidence and costs of cardiovascular events in Spanish patients with type 2 diabetes mellitus: a comparison with general population, 2015
    Esteban Jódar, Sara Artola, Xavier García–Moll, Estefany Uría, Noemí López-Martínez, Rosa Palomino, Virginia Martín · 2020 · BMJ Open Diabetes Research & Care
  12. Long-term diabetes outcomes after bariatric surgery—managing medication withdrawl
    Multidisciplinary Group for Surgical Management of Obesity, Pedro Souteiro, Sandra Belo, Daniela Mendes dos Santos Magalhães, Jorge Manuel Pires Pedro, João Sérgio Neves, Sofia Castro Oliveira, Paula Freitas, Ana Teresa Inácio Ferreira Varela, Davide Maurício Carvalho · 2019 · International Journal of Obesity
  13. Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53)
    Maegawa, Hiroshi, Ishigaki, Yasushi, Langer, Jakob, Saotome‐Nakamura, Ai, Andersen, Marc, the Japan Diabetes Clinical Data Management (JDDM) Study Group · 2021 · Journal of Diabetes Investigation
  14. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes
    Rohit Vashisht, Ayan R. Patel, Lisa Dahm, Cora Han, Kathryn E. Medders, Robert M. Mowers, Carrie L. Byington, Suneil K. Koliwad, Atul Janardhan Butte · 2023 · JAMA Network Open
  15. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study
    Reema Mody, Qing Huang, Maria B. Yu, Hiren Patel, Xian Zhang, Liya Wang, Michael Grabner · 2019 · BMJ Open Diabetes Research & Care
  16. Clinical and Public Health Implications of 2019 Endocrine Society Guidelines for Diagnosis of Diabetes in Older Adults
    Michael Fang, Justin Basile Echouffo-Tcheugui, Elizabeth Selvin · 2020 · Diabetes Care
  17. GLP-1 Receptor Agonists in Orthopaedic Surgery: Implications for Perioperative Care and Outcomes
    Rahul Ramanathan, Joon Y. Lee, Jonathan Dalton, Ryan T. Lin, Isaac Lee, Christopher Gonzalez, Jeremy D. Shaw, Gregory Douglas Schroeder, Christopher K. Kepler, Michael J. Spitnale et al. · 2025 · Journal of Bone and Joint Surgery
  18. Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence
    Shang‐Feng Tsai, Cheng‐Hsu Chen · 2019 · International Journal of Molecular Sciences
  19. Personalized Management of Type 2 Diabetes
    Patricia R. Peter, Beatrice C. Lupsa · 2019 · Current Diabetes Reports
  20. Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration
    Lee‐Shing Chang, Muthiah Vaduganathan, Jorge Plutzky, Vanita R. Aroda · 2019 · Current Diabetes Reports
  21. A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment
    Arshiya Mariam, Galen A. Miller-Atkins, Kevin M. Pantalone, Robert S. Zimmerman, John Barnard, Michael W. Kattan, Hetal Shah, Howard L. McLeod, Alessandro Doria, Michael J. Wagner et al. · 2021 · Diabetes Care
  22. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study
    Terri Victoria Newman, Kiraat D. Munshi, Lynn M. Neilson, Chester B. Good, Elizabeth C.S. Swart, Yan Huang, Rochelle R. Henderson, Natasha Parekh · 2021 · Journal of Managed Care & Specialty Pharmacy
  23. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for Treatment of Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Study
    Ling Qu, Xiao‐chun Liang, Guoqing Tian, Gai-li Zhang, Qunli Wu, Xiumei Huang, Yazhong Cui, Yuling Liu, Zhufang Shen, Guoqing Ma et al. · 2022 · Chinese Journal of Integrative Medicine
  24. Ketogenic Diet Regulates Cardiac Remodeling and Calcium Homeostasis in Diabetic Rat Cardiomyopathy
    Ting-I Lee, Nguyen Ngoc Trang, Ting‐Wei Lee, Satoshi Higa, Yu‐Hsun Kao, Yao‐Chang Chen, Yi‐Jen Chen · 2023 · International Journal of Molecular Sciences
  25. Nuevos fármacos para la reducción del riesgo cardiovascular en pacientes con diabetes mellitus tipo 2
    Juan José Gorgojo Martínez · 2019 · Hipertensión y Riesgo Vascular
  26. Cost-effectiveness analysis of comprehensive intervention programs to control blood glucose in overweight and obese type 2 diabetes mellitus patients based on a real-world setting: Markov modeling
    Hui Wang, Mengyang Wang, Jiao Wang, Hongwei Liu, Rui Lu, Tongqing Duan, Xiaowen Gong, Siyuan Feng, Zhuang Cui, Yuanyuan Liu et al. · 2019 · Annals of Translational Medicine
  27. Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study
    Xuejun Peng, Rajeev Ayyagari, ROBERT N. LUBWAMA, Lizheng Shi, Eboni G. Price‐Haywood, Priscilla A. Hollander, Vivian Andrew Fonseca · 2020 · Diabetes Therapy
  28. Glycaemic and non‐glycaemic efficacy of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
    Dhiren K Patel · 2020 · Journal of Clinical Pharmacy and Therapeutics
  29. Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme
    Daisy Precilla Senthilathiban, Shreyas S. Kuduvalli, Mugilarasi Purushothaman, Parthiban Marimuthu, Arumugam Ramachandran Muralidharan, T. S. Anitha · 2021 · Current Molecular Pharmacology
  30. From iPSCs to Pancreatic β Cells: Unveiling Molecular Pathways and Enhancements with Vitamin C and Retinoic Acid in Diabetes Research
    F. Arroyave, Y. Uscátegui, F. Lizcano · 2024 · International Journal of Molecular Sciences
  31. Hypoglycemia in patients with type 2 diabetes treated with oral antihyperglycemic agents detected by continuous glucose monitoring: a multi-center prospective observational study in Croatia
    Maja Baretić, Valerija Bralić Lang · 2020 · BMC Endocrine Disorders
  32. Managing the multifaceted nature of type 2 diabetes using once‐weekly injectable GLP‐1 receptor agonist therapy
    Andrew S. Bzowyckyj · 2020 · Journal of Clinical Pharmacy and Therapeutics
  33. Neuroimaging perspective in targeted treatment for type 2 diabetes melitus and sleep disorders
    Karen M. von Deneen, Malgorzata Anna Garstka · 2022 · Intelligent Medicine
  34. Adaptive Treatment Strategies With Survival Outcomes: An Application to the Treatment of Type 2 Diabetes Using a Large Observational Database
    Gabrielle Simoneau, Erica E. M. Moodie, Laurent Azoulay, Robert William Platt · 2019 · American Journal of Epidemiology
  35. ¿Cuándo empieza la diabetes? Detección e intervención tempranas en diabetes mellitus tipo 2
    Fernando Gómez Peralta, Cristina Abreu, Xavier Cos, Ricardo Gómez‐Huelgas · 2020 · Revista Clínica Española
  36. Evaluation of a Pharmacist-Led Intervention to Improve Statin Use in Persons with Diabetes
    Sarah L. Anderson, Joel C. Marrs, Cynthia R. Chachas, Brian S. Cichon, Amber D. Cizmic, Bianca B. Calderon, Tara Behring Vlasimsky · 2020 · Journal of Managed Care & Specialty Pharmacy
  37. Comorbidities in type 2 diabetes patients with and without atherosclerotic cardiovascular disease: a retrospective database analysis
    Kristy Iglay, Hakima Hannachi, Samuel S. Engel, Xueying Li, David O’Connell, Lori M. Moore, Swapnil N. Rajpathak · 2021 · Current Medical Research and Opinion
  38. Tirzepatide: Clinical review of the twincretin injectable
    Krauss, Zach, Hintz, Alexandra, Fisk, Rebecca · 2023 · American Journal of Health-System Pharmacy
  39. The “Early Treatment” Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique
    Giuseppina Tiziana Russo, Matteo Monami, Gianluca Perseghin, Angelo Avogaro, Pasquale Perrone Filardi, Michele Senni, Claudio Borghi, Aldo Pietro Maggioni · 2021 · Diabetes Therapy
  40. Lifestyle modification in the management of insulin resistance states in overweight/obesity: the role of exercise training
    Tshidi Thaane, Ayesha Ahmed Motala, Andrew J. McKune · 2019 · Journal of Endocrinology Metabolism and Diabetes of South Africa
  41. The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis
    Emanuela Talamonti, Jelena Davegardh, Anastasia Kalinovich, Sten M. M. van Beek, Nodi Dehvari, Carina Halleskog, Muhammad Hamza Bokhari, Dana S. Hutchinson, Seungmin Ham, Laura J. Humphrys et al. · 2024 · Molecular Metabolism
  42. Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs
    Linda M. Hunt, Elisabeth Arndt, Hannah S. Bell, Heather Howard · 2021 · Journal of Bioethical Inquiry
  43. The Transcultural Diabetes Nutrition Algorithm: A Middle Eastern Version
    Osama Hamdy, Saud Al Sifri, Mohamed M. Hassanein, Mohammed A. Al Dawish, Raed Aldahash, Fatheya Alawadi, Nadim S. Jarrah, Hajar Ahmad Ballout, Refaat A. F. Hegazi, Ahmed Amin et al. · 2022 · Frontiers in Nutrition
  44. Egészségügyi szakmai irányelv : A diabetes mellitus kórismézéséről, a cukorbetegek antihyperglykaemiás kezeléséről és gondozásáról felnőttkorban
    J. Róbert Bedros, György Jermendy, Zsolt Gaál, László Gerő, Tibor Hídvégi, Péter Kempler, Csaba Lengyel, Tamás T. Várkonyi, Gábor Winkler, István Wittmann · 2023 · Diabetologia Hungarica
  45. Evaluation of vitamin B12 monitoring in patients on metformin in urban ambulatory care settings
    Stacy L Longo, Jessica M Ryan, Kelsey Sheehan, Debra J. Reid, Michael P. Conley, Carla J. Bouwmeester · 2019 · Pharmacy Practice
  46. Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
    Yehuda Handelsman, Marcel H.A. Muskiet, Graydon S. Meneilly · 2019 · Advances in Therapy
  47. C-peptide concentrations in patients with type 2 diabetes treated with insulin
    Mehmet Uzunlulu, Aytekin Oğuz, Müzeyyen Arslan Bahadır, Ayşe Naciye Erbakan, Miraç Vural Keskinler, Banu Mesçi · 2019 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  48. Documentation of hypoglycemia assessment among adults with diabetes during clinical encounters in primary care and endocrinology practices
    on behalf of the Hypoglycemia as a Quality Measure in Diabetes Study Group, René Rodríguez‐Gutiérrez, Alejandro Salcido‐Montenegro, Naykky Singh Ospina, Spyridoula Maraka, Nicole M. Iñiguez‐Ariza, Gabriela Spencer‐Bonilla, Shrikant U. Tamhane, Kasia J. Lipska, Víctor M. Montori et al. · 2019 · Endocrine
  49. Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials
    Qian Lv, Jie Shen, Lin Miao, Binqi Ye, Cornelia Schepers, Arian W. Plat, Yongquan Shi · 2020 · Diabetes Therapy
  50. Diabetes, Therapeutic Inertia, and Patients’ Medication Experience
    Andrew S. Bzowyckyj, John E. Begert · 2020 · Diabetes Spectrum
  51. Impressive clinical course of diabetic patient with various medical problems and remarkable improvement by insulin degludec and liraglutide (Xultophy)
    Hiroshi Bando · 2020 · MOJ Clinical & Medical Case Reports
  52. Potential Therapeutic Applications of Synthetic Conotoxin s-cal14.2b, Derived from Californiconus californicus, for Treating Type 2 Diabetes
    Pavel H. Lugo-Fabres, Leslie M. Otero-Sastre, Johanna Bernáldez-Sarabia, Tanya Amanda Camacho-Villegas, Noemí Sánchez-Campos, Janeth Serrano‐Bello, Luis A. Medina, Saé Muñiz‐Hernández, Lizbeth de la Cruz, Isabel Arenas et al. · 2021 · Biomedicines
  53. 3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy
    Caroline E. El Sanadi, Xinge Ji, Michael W. Kattan · 2020 · Annals of Translational Medicine
  54. Evolution of Clinical Complexity, Treatment Burden, Health Care Use, and Diabetes-Related Outcomes Among Commercial and Medicare Advantage Plan Beneficiaries With Diabetes in the U.S., 2006–2018
    Tyler J. Benning, Herbert C. Heien, Rozalina G. McCoy · 2022 · Diabetes Care
  55. RE: Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2019 Executive Summary
    Héctor Eloy Tamez-Pérez, Eduardo Enrique González-Guajardo, Alejandra Lorena Tamez-Peña · 2019 · Endocrine Practice
  56. Use of glucose‐lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose‐lowering drug groups
    Márta Csatordai, Ria Benkő, Mária Matúz, A Bor, Csaba Lengyel, Péter Doró · 2019 · Diabetic Medicine
  57. Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist’s Perspective
    Zhihui Song, Xinglong Wang, Xiaofeng Wang, Jing Liu, Sang-Quzhen Luo, Shan-Shan Xu, Cheng Xiao, Jie Bai, Liming Dong, Chao Zhang et al. · 2022 · Frontiers in Endocrinology
  58. Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus.
    Pragya Rai, Nilanjana Dwibedi, Mazhgan Rowneki, Drew A. Helmer, Usha Sambamoorthi · 2019 · PubMed Central
  59. Efficacy and safety of Shenqi Jiangtang Granules plus oral hypoglycemic agent in patients with type 2 diabetes mellitus
    Tianli Li, Wanqing Li, Yang Wu, Qian Wu, Guozhen Zhao, Zhaolun Cai, Fenglan Pu, Bo Li · 2021 · Medicine
  60. Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial
    Yihong Deng, Eric C. Polley, Joshua David Wallach, Jeph S. Herrin, Joseph S. Ross, Rozalina G. McCoy · 2023 · BMJ Medicine
  61. A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country
    Nancy Zaghloul, Ahmed Awaisu, Ahmed Mahfouz, Sumaya Alyafei, Hazem Fathy Elewa · 2022 · International Journal of Clinical Pharmacy
  62. Type 2 diabetes: Evolving concepts and treatment
    Eden M Miller, Richard B. Aguilar, Mary E. Herman, Stanley S. Schwartz · 2019 · Cleveland Clinic Journal of Medicine
  63. Evidence‐based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease
    Katherine R. Tuttle, Janet B. McGill · 2020 · Diabetes Obesity and Metabolism
  64. Diabetes: an Overview for Clinical Oncologists
    Y.-N. Lee, Tahseen Ahmad Chowdhury · 2020 · Clinical Oncology
  65. The Successful Rapid Adjustment of Blood Glucose in a Patient With Acute Coronary Syndrome, Renal Insufficiency, and Diabetes: A Case Report of Management Coordinated by Clinical Pharmacists and Clinicians
    Fang‐Hong Shi, Long Shen, Mang-Mang Pan, Linlin Ma, Chi Zhang, Zhi‐Chun Gu, Jing Ma, Hao Li · 2020 · Frontiers in Pharmacology
  66. Development and evaluation of a patient-centered quality indicator for the appropriateness of type 2 diabetes management
    Rozalina G. McCoy, Kasia J. Lipska, Holly K. Van Houten, Nilay D. Shah · 2020 · BMJ Open Diabetes Research & Care
  67. What are the factors associated with long‐term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second‐line therapy? Results from the DISCOVER study
    Fabrice Bonnet, Hungta Chen, Andrew Cooper, Marília Brito Gomes, Linong Ji, Paul Leigh, Larisa Ramirez, Marina Vladimirovna Shestakova, Iichiro Shimomura, Afrah Siddiqui et al. · 2021 · Diabetes Obesity and Metabolism
  68. HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
    Anita Y. M. Kwan, Hertzel C. Gerstein, Jan Basile, Denis Xavier, Juan M. Maldonado, Sohini Raha, Маниге Кониг · 2022 · Diabetes Care
  69. Effectiveness of sodium‐glucose co‐transporter‐2 inhibitors on ischaemic heart disease
    Yun Shen, Jian Zhou, Lizheng Shi, Elizabeth Nauman, Peter Todd Katzmarzyk, Eboni G. Price‐Haywood, Ronald L. Horswell, San T. Chu, Shengping Yang, Alessandra N. Bazzano et al. · 2020 · Diabetes Obesity and Metabolism
  70. Diabetes distress is associated with individualized glycemic control in adults with type 2 diabetes mellitus
    Konstantina Th. Theodoropoulou, George Dimitriadis, Nikolaοs Tentolouris, Christina Darviri, George Panagiotis Chrousos · 2020 · HORMONES
  71. Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC
    Zachary T. Bloomgarden, Yehuda Handelsman · 2020 · American Journal of Preventive Cardiology
  72. Diabetes mellitus progression in β-thalassaemia major patients: The impact of iron overload
    Eglal Mahgoub, Reem A. Qannita, Ayah Alalami, Ola Al Shehadat, Rabah Almahmoud, Ayah Dib, Alaa Al Hajji, Amani Al Hajji, Fatheya Alkhaja, Hany Dewedar et al. · 2024 · Advances in Biomedical and Health Sciences
  73. The Impact of SARS-CoV-2 Infection on Glucose Homeostasis in Hospitalized Patients with Pulmonary Impairment
    Oana-Andreea Parlițeanu, Mara Amalia Bălteanu, Dragos Cosmin Zaharia, Tudor Constantinescu, Alexandra Maria Cristea, Stefan Dumitrache‐Rujinski, Andra Elena Nica, Cristiana Voineag, Octavian Alexe, Emilia Tabacu et al. · 2025 · Diagnostics
  74. Patients’ Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation
    José E Costa Gil, Juan C. Garnica-Cuéllar, Paula Pérez Terns, Aldo Ferreira‐Hermosillo, José Antonio Cetina Canto, Ángel Alfonso Garduño-Pérez, Pedro Mendoza Martínez, Lucas Rista, Alejandro Sosa-Caballero, Estefanía Vázquez-Méndez et al. · 2022 · Patient Preference and Adherence
  75. New Trends and Therapies for Familial Hypercholesterolemia
    Fahad Alnouri, Raul Dias Santos · 2022 · Journal of Clinical Medicine
  76. Assessment of the benefit–risk balance of SGLT2 inhibitors: Commentary on a new ‘French paradox’
    André Jacques Scheen, Patrice Darmon, Hélène P. Hanaire · 2019 · Diabetes & Metabolism
  77. VERIFY the role of initial combination therapy in patients with type 2 diabetes
    Ofri Mosenzon, Gil Leibowitz · 2019 · The Lancet
  78. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets
    Anthony J. Cannon, Αlexandra Bargiota, Liana K. Billings, Barnaby Hunt, Lawrence A. Leiter, Samuel J. P. Malkin, Michelle Mocarski, Mattis Flyvholm Ranthe, Alisa B. Schiffman, Ankur Doshi · 2019 · Journal of Managed Care & Specialty Pharmacy
  79. Engaging Underserved Community Members in Diabetes Self-Management: Evidence From the YMCA of Greater Richmond Diabetes Control Program
    Julie Ober Allen, Jeannie B. Concha, María José Mejía Ruiz, Ashley Redding, Joshua Montgomery, Jana Smith, Julia A. Wolfson, William Thornton, Briana R. Mezuk · 2020 · The Science of Diabetes Self-Management and Care
  80. Glycemic variability in patients with gastrointestinal cancer: An integrative review
    Natalie Rasmussen Mandolfo, Ann M. Berger, Marilyn J. Hammer · 2020 · European Journal of Oncology Nursing
  81. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects
    Daniel A. Duprez, Yehuda Handelsman, Michael J. Koren · 2020 · Vascular Health and Risk Management
  82. Continuous Glucose Monitors as Wearable Lifestyle Behavior Change Tools in Obesity and Diabetes
    Susan M. Schembre, Yue Liao, Michelle Rose Jospe · 2020 · Springer eBooks
  83. Diabetes Rescue, Engagement and Management (D-REM): rationale and design of a pragmatic clinical trial of a community paramedicine programme to improve diabetes care
    Michael B. Juntunen, Chad P. Liedl, Peter N. Carlson, Lucas A. Myers, Zachary R. Stickler, Jill Ryan Schultz, ANGELA K. MEILANDER, Emma Behnken, Michelle A. Lampman, M Carson Rogerson et al. · 2022 · BMJ Open
  84. The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring
    Pamela R. Kushner, Davida F. Kruger · 2020 · Clinical Diabetes
  85. Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study
    Rozalina G. McCoy, Jonathan L. Vandergrift, Bradley Michael Gray · 2025 · Diabetes Research and Clinical Practice
  86. Effect of routinely assessing and addressing depression and diabetes distress using patient-reported outcome measures in improving outcomes among adults with type 2 diabetes: a systematic review protocol
    Rita McMorrow, Barbara Hunter, Christel Hendrieckx, Dominika Kwaśnicka, Leanne Cussen, Felicia Ching Siew Ho, Jane Speight, Jon David Emery, Jo-Anne Elizabeth Manski-Nankervis · 2021 · BMJ Open
  87. Use of Endocrine Consultation for Hemoglobin A1C ≥9.0% as a Standardized Practice in an Emergency Department Observation Unit
    Rifka Schulman‐Rosenbaum, Nina Hadzibabic, Katherine Cuan, Donna L. Jornsay, Elissa Wolff, Allison Tiberio, Dana Gottlieb, Frederick Davis, Robert A. Silverman · 2021 · Endocrine Practice
  88. Sodium-glucose co-transporter 2 inhibitors and heart failure—the present and the future
    Melanie Nana, Holly Morgan, L. N. Rao Bondugulapati · 2020 · Heart Failure Reviews
  89. Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial
    Jae Hyun Bae, Chang Ho Ahn, Ye Yang, Sun Joon Moon, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho · 2021 · Diabetes & Metabolism Journal
  90. Identification of biomarkers and mechanism exploration of ferroptosis related genes regulated by m6A in type 2 diabetes mellitus
    Jing Wang, Xuying Li, Juan Geng, Ruiduo Wang, Gang Ma, Pan Liu · 2025 · Hereditas
  91. Early prescription of SGLT2i for acute patient care: from current evidence to future directions
    Fabrizio Ricci, Silvio Saraullo, Andrea Boccatonda, Anna Sorella, Alessia Cipollone, Paola Simeone, Sabina Gallina, Francesca Santilli, Francesco Cipollone, Damiano D’Ardes · 2025 · Current Problems in Cardiology
  92. Prise de position de la Société Francophone du Diabète (SFD) : évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2
    Bernard Bauduceau, L. Bordier, J. Bringer, G. Chabrier, Bernard H. Charbonnel, Emmanuel Cosson, Patrice Darmon, B. Detournay, Pierre Fontaine, Pierre Gourdy et al. · 2019 · Médecine des Maladies Métaboliques
  93. Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement
    Bruce A. Warden, Johannes Steiner, Albert Camacho, Khoa Anh Nguyen, Jonathan Q. Purnell, Paul Barton Duell, Courtney Craigan, Diane Osborn, Sergio Fazio · 2021 · American Journal of Preventive Cardiology
  94. Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus
    Vikram Sharma, Shalini Chawla, Sandeep Garg, Bhupinder Singh · 2024 · Sultan Qaboos University medical journal
  95. RSPO3 is a novel contraction-inducible factor identified in an “in vitro exercise model” using primary human myotubes
    Tadahisa Takahashi, Yuqing Li, Weijian Chen, Mazvita R. Nyasha, Kazumi Ogawa, Kazuaki Suzuki, Masashi Koide, Yoshihiro Hagiwara, Eiji Itoi, Toshimi Aizawa et al. · 2022 · Scientific Reports
  96. Capacity and confidence building for general practitioners on optimum insulin use
    Abhay I Ahluwalia, Sanjay Kalra, Prasun Deb, Kalyan Kumar Gangopadhyay, Sunil Gupta · 2019 · Journal of Family Medicine and Primary Care
  97. Continuous Glucose Monitoring
    Joshua P. Rickard · 2021 · Elsevier eBooks
  98. Novel trends and concepts in the nutritional management of glycemia in type 2 diabetes mellitus—beyond dietary patterns: a narrative review
    Zoe Pafili, Charilaos Dimosthenopoulos · 2021 · HORMONES
  99. The The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network.
    Vincenzo De Sanctis, Ashraf Tawfik Soliman, Ploutarchos Tzoulis, Shahina Daar, Antonis Kattamis, Polyxeni Delaporta, Mehran Karimi, Mohamed A. Yassin, Tahereh Zarei, Forough Saki et al. · 2022 · Acta bio-medica dell'Ateneo parmense/Acta biomedica
  100. Dorzagliatin for Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Phase II/III Trials
    Fei Lin, Rong Xing He, Baodong Ling, Lin Wang, Ting Jiang, Bin Yu · 2023 · Clinical Therapeutics